Mast cells modulate transport of CD23/IgE/antigen complex across human intestinal epithelial barrier

Ya-Hong Tu*, Christine Oluwole¶, Stevie Struiksma¶, Mary H. Perdue*, Ping-Chang Yang¶

*Intestinal Disease Research Program, ¶The McMaster Brain-Body Institute, St. Joseph’s Healthcare, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada

Background: Food allergy and chronic intestinal inflammation are common in western countries. The complex of antigen/IgE is taken up into the body from the gut lumen with the aid of epithelial cell-derived CD23 (low affinity IgE receptor II) that plays an important role in the pathogenesis of intestinal allergy. This study aimed to elucidate the role of mast cell on modulation of antigen/IgE complex transport across intestinal epithelial barrier. Methods: Human intestinal epithelial cell line HT29 cell monolayer was used as a study platform. Transepithelial electric resistance (TER) and permeability to ovalbumin (OVA) were used as the markers of intestinal epithelial barrier function that were recorded in response to the stimulation of mast cell-derived chemical mediators. Results: Conditioned media from naïve mast cell line HMC-1 cells or monocyte cell line THP-1 cells significantly upregulated the expression of CD23 and increased the antigen transport across the epithelium. Treatment with stem cell factor (SCF), nerve growth factor (NGF), retinoic acid (RA) or dimethyl sulphoxide (DMSO) enhanced CD23 expression in HT29 cells. Conditioned media from SCF, NGF or RA-treated HMC-1 cells, and SCF, NGF, DMSO or RA-treated THP-1 cells enhanced immune complex transport via enhancing the expression of the CD23 in HT29 cells and the release of inflammatory mediator TNF-α. Nuclear factor kappa B inhibitor, tryptase and TNF-α inhibited the increase in CD23 in HT29 cells and prevents the enhancement of epithelial barrier permeability. Conclusions: Mast cells play an important role in modulating the intestinal CD23 expression and the transport of antigen/IgE/CD23 complex across epithelial barrier. (Tu YH, Oluwole C, Struiksma S, Perdue MH, Yang PC. Mast cells modulate transport of CD23/IgE/antigen complex across human intestinal epithelial barrier. North Am J Med Sci 2009; 1: 16-24).

Key words: Intestine; Epithelium; Barrier function; Mast cells; Allergy.

Introduction

Our previous studies [1-3] indicated that intestinal epithelial cell express the low affinity IgE receptor (FceRII or CD23). We recent found that the function of epithelial cell-derived CD23 forming complex with IgE that facilitates the specific antigen transport across intestinal epithelial barrier. In a mouse model of food allergy and in a human intestinal epithelial cell culture system, IgE receptor expression was shown to be upregulated by the Th2 cytokine IL-4 [3-6], thereby facilitating IgE and IgE-antigen immune complexes to be transported across intestinal epithelial barrier. Transport of intact antigen into intestinal mucosa has the potential in resulting in the immediate hypersensitivity reaction or/and leads to systemic anaphylaxis. However, the modulating factors on antigen/IgE transport across intestinal epithelial barrier are to be further understood. In the human fetus and naïve adult rodents, there is little or no expression of CD23 protein in intestinal epithelial cells. However, in adult human, sensitized rodents, and human fetal intestine stimulated with IL-4, intestinal epithelial cells express CD23 [3, 7-8]. The expression of CD23 in epithelial cells is upregulated in the intestine of the patients with Crohn’s disease, ulcerative colitis with cow’s milk allergy [9]. Patients with Crohn’s disease have increased antigen uptake into the intestine [10]. These findings suggest that hypersensitivity and inflammation may affect intestinal CD23 expression and its function with respect to transepithelial antigen transport.

Mast cell is a major effector cell in allergic reactions. Mast cells also play an important role in both acute and chronic inflammation [11, 12]. In addition, in chronic inflammatory and allergic diseases, various types of inflammatory cells infiltrate in inflammatory sites. Interactions between inflammatory cells and intestinal epithelial cells may result in cytokine expression and/or direct injury to the epithelium and thus compromise the epithelial barrier function.

Under normal conditions, mast cells are distributed throughout connective tissues and beneath epithelium. Mast cells originated from bone marrow progenitor cells that migrate into the circulation as morphologically indistinct precursors. After being recruited to different tissues they complete their differentiation under the influence of stem cell
Materials and Methods

**Reagents:** CD23 antibody (clone Tu1. NovoCastra Laboratories Ltd, Newcastle upon Tyne, UK). Anti-tryptase antibody (DAKO Diagnostics Canada, Mississauga, ON, Canada). Chimeric human IgE raised against 4-hydroxy-3-nitrophenylacetyl (NP) (Serotec Inc. Oxford, UK). NP (16-OVA (Biosearch Technologies Inc. Novato, CA). SCF, NGF and IL-6 (Leinco Technologies. St. Louis, Missouri, US). BAY 11-7082 (Bay 11) (Calbiochem-Novabiochem; San Diego, USA). BAY 11-7082 is a potent NF-κB inhibitor. It inhibits NF-κB p65-DNA binding activity and IkB kinase (IKK-α) protein expression [35]. Inhibition of p38 MAP kinase and NF-κB-signaling suppresses the inflammatory bowel disease [36].

TNF-α and tryptase are critical factors in affecting and regulating intestinal epithelial barrier function. Addition of TNF-α decreases the transepithelial electrical resistance (TER) via altering structure and function of tight junction [37]. The intestine highly expresses proteinase-activated receptor-2 (PAR-2). Trypsin and mast cell-derived tryptase are the agonists of PAR2. Administration of PAR2 agonist activated PAR-2 receptors in the epithelium, and increased epithelial barrier permeability [38]. Therefore, we hypothesized that mast cell-derived mediators might affect intestinal epithelial barrier function by modulating the expression of CD23 and the specific antigen transport across intestinal epithelial barrier. In this study, we used an in vitro cell system and found that mast cells did have the capacity in modulating the expression of intestinal epithelial CD23 and transepithelial transport of antigen.

**Cell Culture:** HT29-C1 19A human intestinal epithelial cells were cultured in McCoy’s 5A modified medium without glucose, supplemented with 5% FBS, 0.0375 % sodium bicarbonate, 0.2 mM L-glutamine, and penicillin/streptomycin. The cells were split every five days, culture media were changed every two or three days. 8 × 10^5 cells were seeded onto a transwell filter (Corning Inc., Corning, New York). The cells were cultured in a 50 ml conical tube with 25 ml media for 7 days in an atmosphere of 5% CO2 at 37°C. The filter was returned to the Transwell compartment when the transepithelial resistance was at least 400 Ω/cm² measured by an Ohm meter with chopstick electrodes (Millicell-RES; Millipore, Bedford, MA). Under these conditions, the cells formed differentiated monolayer as viewed by electron microscopy (data not shown).

HMC-1 and THP-1 cells were cultivated in RPMI 1640 medium, supplemented with 10% fetal calf serum, 2.25 mM L-glutamine, 27 mM HEPES and penicillin/streptomycin. The cells were treated with SCF (50 ng/ml), NGF (20 ng/ml), retinoic acid (1μM) or IL-6 (2 ng/ml) or DMSO (1 %) for 7 days. The concentrations of the inflammatory reagents were referred to published data [39, 40, 15, 16] or determined by our preliminary experiments.

**Measurements of CD23 and Tryptase by Western Blot:** After treatment, cells were washed twice with cold PBS (pH 7.2), containing a cocktail of protease inhibitors. Cells were harvested by scraping in 500 μl ice-cold lyses buffer (100 mM NaCl, 10 mM Tris·HCl, 2 mM EDTA, 1.8 % triton X-100 and protease inhibitors) at pH 7.8 [3, 41]. Protein in the lysates was measured by Bio-Rad protein assay kit. 80 μg of protein for each sample was separated on a 10% acrylamide gel. The proteins were transferred electrophoretically onto a nitrocellulose membrane, and incubated with anti-human CD23 antibody (1:500) for 48h or anti-human mast cell tryptase overnight at 4°C. After washing with 0.01 M PBS, the membrane was incubated with horseradish peroxidase (HRP) conjugated...
secondary antibody for 1 h at room temperature. The target protein was detected by the enhanced chemiluminescence (ECL) detection system and recorded by X-ray film. The integrated intensity of the blots was quantified by scanning densitometry.

Measurement of TNF-α and Histamine by enzyme-linked immunosorbent assay (ELISA):

10⁶ of either HMC-1 mast cells or THP-1 cells were seeded into a flask with 5 ml culture media. The cells were treated with inflammatory reagents and cultured for 7 days. TNF-α and histamine in the supernatant was measured by ELISA.

Assessment of transport of IgE-antigen Immune Complex:

An immune complex of IgE anti NP and NP-OVA was made by incubation of the IgE anti NP (0.2 µM) and NP-OVA (0.5 µM) in the IgE binding buffer (in mM: 10 Tris•HCl (pH 7.35), 140 NaCl, 2 CaCl₂, and 1 MgCl₂, with 1.8 g/l glucose) for 1 hour. The complex was added to the apical or basal compartment of transwell system. After incubation at 37°C, 5% CO₂ atmosphere, media in the basal or apical compartment of the monolayer were collected and analyzed by western blotting assay. A secondary antibody to OVA (1:20,000) was employed to detect the NP-OVA [41].

Statistical Analysis:

Data were presented as means ± SE. Differences of means were analyzed by two-tail student t test between two groups or ANOVA if more than two groups. p < 0.05 was considered to be significant.

Results

Upregulation of intestinal epithelial CD23 protein by conditioned media from HMC-1 mast cells, THP-1 monocytes, but not EBV-transformed B lymphocytes

Incubation of the HT29 monolayer with the vehicle or conditioned medium from 7 days upregulated the expression of CD23 protein by intestinal epithelial cells by 80% as compared with those HT29 cells incubated with normal medium (vehicle). The CD23 protein expression in HT29 cells was further enhanced by the conditioned media from SCF, NGF, DMSO and RA-treated HMC-1 cell culture, but not by the supernatant from IL-6-treated HMC-1 cell culture (figure 1A).

Using as a comparison, we also observed that incubation of the HT29 cells with the supernatant from THP-1 cell culture with or without the stimulation of inflammatory agents. The expression of CD23 by HT29 cells was increased by 120% (figure 1B).

Alteration of tryptase and histamine production by HMC-1 cells by exposure to inflammatory agents

Tryptase and histamine are the major chemical mediators of mast cells that can be released into the vicinity of cells and induce inflammatory reactions. To elucidate the underlying mechanism by which supernatant of HMC-1 cells induced CD23 expression in HT29 cells, we evaluated the levels of tryptase and histamine in culture media of HMC-1 cells in the presence or absence of inflammatory agents. As shown by ELISA data, SCF and DMSO had powerful effect on histamine release from HMC-1 cells while retinoic acid markedly increased the released of tryptase into culture media. (figure 2A).

In observation of histamine release from HMC-1 cells in response to exposure to inflammatory agents, different results were noted as compared with that from tryptase release. SCF and DMSO had powerful effect on histamine release from HMC-1 cells while retinoic acid had less effect, NGF had no effect on histamine release (figure 2B).

Alteration of TNF-α in the culture media of HMC-1 and THP-1 cells after treatment

TNF-α is an important proinflammatory mediator that is involved in a broad array of inflammatory disorders. Mast cells have a unique feature that can synthesize TNF-α and
store it in cellular granules to be released upon activation. To elucidate if other inflammatory agents had any effects on TNF-α release from mast cells, HMC-1 cells were cultured for 7 days in the presence or absence of the inflammatory agents as aforementioned. As shown by ELISA data, treatment of HMC-1 with SCF or NGF for 7 days, no significant change of TNF-α was detected in supernatant of HMC-1. However, treatment of the HMC-1 with DMSO, or retinoic acid for 7 days, markedly decrease in TNF-α was noted in culture media. The results indicate that DMSO and retinoic acid have the ability to inhibit the release of the TNF-α into the culture media (figure 3A).

We also observed the release of TNF-α in THP-1 cells upon the stimulation of the inflammatory agents. Treatment of THP-1 monocytes with SCF or NGF significantly increased the release of TNF-α in the supernatant whereas treatment with either DMSO or retinoic acid showed inhibitory effect on the release of TNF-α (figure 3B). Treatment with fresh culture medium, no TNF-α was detected.

Effects of conditioned media on specific antigen transport across monolayer epithelial barrier

Conditioned media were collected from cell culture supernatant of HMC-1 or THP-1 cells after exposure to inflammatory agents. The transport of complex of NP-specific IgE/NP-OVA across HT29 monolayer after exposure to

Fig.2. Release of tryptase and histamine from HMC-1 mast cells
HMC-1 cells were cultured in the presence of inflammatory agents for 7 days. Bars indicate the levels of tryptase (A) and histamine (E) in culture media that were determined by ELISA. *p<0.05, compared with controls (CM). Data were presented as mean ± SE from 3-5 separate experiments.

Fig.3. Release of TNF-α from HMC-1 or THP-1 cells
Supernatants of the reagent-treated HMC-1 or THP-1 cells were subjected to ELISA for determining levels of TNF-α. Bars indicate the levels of TNF-α.*p<0.05, compared with controls (CM or CT). Data were presented as mean ± SE from four separate experiments to the conditioned media was observed. The results showed that SCF-, NGF-, DMSO- and RA-conditioned media increased the complex transport across HT29 monolayer at 30, 20, 1 and 27 folds respectively (Figure 4A). All conditioned media did not change the TER of HT29 monolayer (figure 4B). The results indicate that these conditioned media do not influence the paracellular pathway of HT29 monolayer, but increase the rate of intracellular transport.

As shown by Figure 5, conditioned media made from THP-1 cells also had similar results on the transport of complex of NP-specific IgE/NP-OVA across HT29 monolayer. SCF-, NGF-, DMSO- and RA-conditioned THP-1 cell culture media increased the transport by 47, 26, 39 or 34 folds respectively.

NF-κB plays a critical role in TNF-α release from THP-1 cells

TNF-α is an important proinflammatory cytokine that is involved in many inflammatory disorders such as inflammatory bowel disease. Monocytes are one of the major sources of TNF-α that can be released to the vicinity in response to noxious stimuli. To understand the mechanism by which conditioned media from THP-1 cells on modulating complex of IgE/antigen transport across intestinal epithelial barrier, we treated THP-1 monocytes with BAY 11-7082 (a NF-κB inhibitor) followed by addition of SCF, NGF, DMSO, or retinoic acid into the culture respectively. As expected, the amount of TNF-α in the supernatant of the THP-1 was dramatically decreased in all the treatment (Figure 6). The
result indicates that NF-κB is a critical molecule in mediating the inflammatory agent-induced intestinal epithelial barrier dysfunction.

Inhibition of tryptase release from HMC-1 mast cells by BAY 11-7082

Tryptase is one of the major chemical mediators in mast cells that is also involved in many inflammatory reactions. Based on the obtained results, we realized that NF-κB might mediate the release of tryptase from mast cells in response to inflammatory agent stimuli. Indeed, pretreatment with NF-κB inhibitor dramatically decreased the tryptase release from HMC-1 cells as compared with controls (figure 7).

NF-κB is a critical mediator in inflammatory agent-enhanced CD23 expression and specific antigen transport across intestinal epithelial barrier

The results above implicate that NF-κB is involved in inflammatory agent-induced increase in CD23 expression in intestinal epithelial cells and IgE/antigen transport across intestinal epithelial barrier. To test the speculation, we pretreated HT29 monolayers with NF-κB inhibitor BAY 11-7082, then exposed the monolayer to conditioned media. Indeed, both increases in CD23 expression in HT29 cells and IgE/antigen transport across HT29 monolayer were inhibited (Fig.8).
Discussion

The relevance between inflammatory cells and the intestinal epithelial cells during food allergy and inflammatory diseases has been identified in many in vivo studies, which provides a crucial image in understanding the mechanism by which inflammatory factors affects intestinal homeostasis and initiates inflammatory disorders. The present study provides further evidence that several inflammatory agents are directly involved in compromising the intestinal epithelial barrier function by facilitating the expression of CD23 molecule in epithelial cells and promoting the IgE/antigen complex transport across intestinal epithelial barrier.

CD23 molecules have been identified as a critical factor in the enhancement of antigen transport across epithelial barrier of sensitized rodents [42, 8]. The increased antigen transport across the intestinal epithelial barrier is specifically via binding to complex of CD23/IgE. The transepithelial antigen transport could be up regulated by Th2 cytokine IL-4. CD23 expression in human intestinal epithelial cells is mediated through the p38 MAPK pathway; inhibition of p38 MAPK abrogates the transport of IgE/antigen immune complexes across intestinal epithelial barrier [41]. During the onset of the Crohn’s disease, ulcerative colitis, and cow’s milk allergy [9], epithelial CD23 expression is upregulated in the intestine of patients. Interestingly, patients with Crohn’s disease have increased antigen uptake into the intestine [10]. These findings suggest that hypersensitivity and inflammation may affect intestinal CD23 expression and its function with respect to transepithelial antigen transport. The present study provides further evidence that in addition to IL-4, inflammatory cells and their mediators also affect the intestinal epithelial CD23 expression and CD23/IgE complex-dependent specific antigen transport across epithelial barrier, which is in consistence with the phenomenon observed in the intestinal allergic diseases, indicating the importance of the CD23 in the pathogenesis of allergic disorders and manipulation of CD23 expression has a therapeutic potential for allergic diseases.

It has been shown that inflammatory cells, particularly mast cells and eosinophils, present in local tissue even if it is in asymptomatic periods such as in out-season [43]. Recruitment of the inflammatory cells to allergic sites may promote the local synthesis of IgE antibodies, production of pro-inflammatory factors TNF-α and some others, such as low affinity receptor for IgE (CD23). Tryptase is another harmful mediator from mast cells that is related to compromising the intestinal barrier function [38]. The present study shows that, in control media, there has little IgE-antigen complex being transported across HT29 monolayer. After exposure to conditioned media, the expression of CD23 was significantly increased [44]. The basic level of tryptase in media could influence expression of epithelial CD23 to facilitate specific antigen transport across intestinal epithelial barrier. In the Crohn’s disease, the TNF-α expression upregulated, and caused an increase of the barrier permeability [10]. It is possible that increased TNF-α in the intestine up regulates the expression of CD23 in intestinal epithelial cells; CD23 then forms immune complexes with specific antigens to increase the specific antigen transport across intestinal epithelial barrier.

PAR-2 activation also increased paracellular permeability of the colon after exposure to its agonist, e.g., mast cell-derived tryptase. Disruption of the integrity of the intestinal barrier leads to high volume of uptake intact antigen, bacterial products and other noxious substance from the intestinal lumen [38]. This notion is supported by the present data.

BAY 11-7082 is a potent inhibitor for NF-κB activation that inhibits NF-κB DNA-binding activity, IkB kinase (IKK-α) protein phosphorylation, and the release of inflammatory mediators such as IL-6, IL-8 and TNF-α. In the present study, pretreatment with BAY 11-7082 inhibited the release of TNF-α from HMC-1 or THP-1 cells that further inhibited the expression of CD23 in intestinal epithelial cells, reduced TER and permeability to IgE/antigen complexes. The fact indicates that NF-κB is a critical molecule in inflammatory agents
induced CD23 expression and intestinal epithelial barrier dysfunction.

In summary, the present study revealed that inflammatory agents drove mast cells and monocytes to release inflammatory cytokine TNF-α; the latter increased the expression of CD23 in intestinal epithelial cells, compromise intestinal epithelial barrier function and facilitated the transport of antigen/IgE/CD23 across intestinal epithelial barrier.

Acknowledgement: This study was supported by grants from the Canadian Institutes of Health Research (CIHR) and the Natural Science and Engineering Council of Canada. Dr. P.C. Yang holds a New Investigator Award of CIHR.

References

1. Yu LC, Montagnac G, Yang PC, Conrad DH, Benmerah A, Perdue MH: Intestinal epithelial CD23 mediates enhanced antigen transport in allergy: evidence for novel splice forms. Am J Physiol Gastrointest Liver Physiol 2003, 285: G223-G234.

2. Montagnac G, Yu LC, Bevilacqua C, Heyman M, Conrad DH, Perdue MH, Benmerah A. Differential Role for CD23 Splice Forms in Apical to Basolateral Transcytosis of IgE/Allergen Complexes. Traffic 2005, 6: 230-242.

3. Tu Y, Salim S, Bourgeois J, Di Leo V, Irvine EJ, Marshall JK, Perdue MH: CD23-mediated IgE transport across human intestinal epithelium: inhibition by blocking sites of translation or binding. Gastroenterology 2005, 129: 928-940.

4. DeFrance T, Aubry JP, Rousset F, Vanbervliet B, Bonnefoy JY, Arai N, Takebe Y, Yokota T, Lee F, Arai K, De Vries J, Banchereau J: Human recombinant interleukin 4 induces Fcε receptors (CD23) on normal human B lymphocytes. J Exp Med 1987, 165: 1459-1467.

5. Hudak SA, Gollnick SO, Conrad DH, Kehry MR: Murine B-cell stimulatory factor 1 (interleukin 4) increases expression of the Fc receptor for IgE on mouse B cells. Proc Natl Acad Sci USA 1987, 84: 4606-4610.

6. Conrad DH, Waldschmidt TJ, Lee WT, Rao M, Keegan AD, Noelle RJ, Lynch RG, Kehry MR: Effect of B cell stimulatory factor-1 (interleukin 4) on Fc epsilon and Fc gamma receptor expression on murine B lymphocytes and B cell lines. J Immunol 1987, 139: 2290-2296.

7. Thornton CA, Holloway JA, Popplewell EJ, Shute JK, Boughton J, Warner JO: Fetal exposure to intact immunoglobulin E occurs via the gastrointestinal tract. Clin Exp Allergy 2003, 33: 306-311.

8. Yang PC, Berin MC, Yu LC, Conrad DH, Perdue MH: Enhanced intestinal transepithelial antioxidant transport in allergic rats is mediated by IgE and CD23 (FcepsilonRII). J Clin Invest 2000, 106: 879-886.

9. Kaiserlian D, Lachaux A, Grosjean I, Graber P, Bonnefoy J-Y: Intestinal epithelial cells express the CD23/FceRII molecule: enhanced expression in enteropathies. Immunology 1993, 80: 90-95.

10. Soderholm JD, Streutker C, Yang PC, Paterson C, Singh PK, McKay DM, Sherman PM, Croitoru K, Perdue MH: Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut 2004, 53: 1817-1824.

11. Galli SJ: New insights into ‘the riddle of the mast cells’: microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 1990, 62: 5-33.

12. Burd PR: Role of cytokines in mast cell function. In: Human Cytokines X. Their role in health and disease. Edited by Aggarwal BB, Puri RK. Cambridge, MA, Blackwell Scientific publications, 1994, pp. 87-99.

13. Okayama Y, Kawakami T: Development, migration, and survival of mast cells. Immunol Res 2006, 34: 97-115.

14. Shiohara M, Koike K: Regulation of mast cell development. Chem Immunol Allergy 2005, 87: 1-21.

15. Nilsson G, Blom T, Kusche-Gullberg M, Kjellen L, Butterfield JH, Sundstrom C, Nilsson K, Hellman L: Phenotypic characterization of the human mast-cell line HMC-1. Scand J Immunol 1994, 39: 489-498.

16. Welker P, Grabbe J, Grutzkau A, Henz BM: Effects of nerve growth factor (NGF) and other fibroblast-derived growth factors on immature human mast cells (HMC-1). Immunology 1998, 94: 310-317.

17. Columbo M, Horowitz EM, Botana LM, McGlashan DW, Bochner BS, Gillis S, Zeseo KM, Galli SJ, Lichtenstein LM: The human recombinant e-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol 1992, 149: 599-608.

18. Takaishi T, Morita Y, Hirai K, Yamaguchi M, Ohta K, Noda E, Morita T, Ito K, Miyamoto T: Effect of cytokines on mediator release from human dispersed lung mast cells. Allergy 1994, 49: 837-842.

19. Taylor AM, Galli SJ, Coleman JW: Dexamethasone or cyclosporine A inhibits stem cell factor-dependent secretory responses of rat peritoneal mast cells in vitro. Immunopharmacol 1996, 34: 63-70.
20. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, Menchaca DM, Gringeri AJ, Schwartz LB, Galli SJ: Recombinant human stem cell factor (Kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996, 183: 2681-2686.

21. Wershil BK, Tsai M, Geissler EN, Zsebo KM, Galli SJ: The rat c-kit ligand, stem cell factor, induces c-kit receptor-dependent mouse mast cell activation in vivo. Evidence that signaling through the c-kit receptor can induce expression of cellular function. J Exp Med 1992, 175: 245-255.

22. Bischoff SC, Dahinden CA: c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med 1992, 175: 237-244.

23. Okayama Y, Hunt TC, Kassel O, Ashman LK, Church MK: Assessment of the anti-c-kit monoclonal antibody YB5.B8 in affinity magnetic enrichment of human lung mast cells. J Immunol Method 1994, 169: 153-161.

24. Bienenstock J, Tomioka M, Matsuda H, Stead RH, Quinonez G, Simon GT, Coughlin MD, Denburg JA: The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions. Int Arch Allergy Appl Immunol 1987, 82: 238-243.

25. Marshall JS, Stead RH, McSharry C, Nielsen L, Bienenstock J: The role of mast cell degranulation products in mast cell hyperplasia. I. Mechanism of action of nerve growth factor. J Immunol 1990, 144: 1886-1892.

26. Lensmar C, Katchar K, Eklund A, Grunewald J, Wahlstrom J: Phenotypic analysis of alveolar macrophages and lymphocytes following allergen inhalation by atopic subjects with mild asthma. Respir Med 2006, 100: 918-925.

27. Varga EM, Jacobson MR, Masuyama K, Rak S, Till SJ, Darby Y, Hamid Q, Lund V, Scadding GK, Durham SR: Inflammatory cell populations and cytokine mRNA expression in the nasal mucosa in aspirin-sensitive rhinitis. Eur Respir J 1999, 14: 610-615.

28. Arm JP, Lee TH: The pathobiology of bronchial asthma. Adv Immunol 1992, 51: 323-382.

29. Kanda N, Watanabe S: 17-estradiol enhances the production of nerve growth factor in THP-1-derived macrophages or peripheral blood monocyte-derived macrophages. J Invest Dermatol 2003, 121: 771-780.

30. Murata-Ohsawa M, Tohda S, Nara N: Cellular analysis of growth suppression induced by the Notch ligands, Delta-1 and Jagged-1 in two myeloid leukemia cell lines. Int J Mol Med 2004, 14: 223-226.

31. Andresen L, Jorgensen VL, Perner A, Hansen A, Eugen-Olsen J, Rask-Madsen J: Activation of nuclear factor kB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 2005, 54: 503-509.

32. Ten RM, McKinstry MJ, Bren GD, Paya CV: Signal transduction pathways triggered by the FcepsilonRIIb receptor (CD23) in human monocytes lead to nuclear factor-kappaB activation. J Allergy Clin Immunol 1999, 104: 376-387.

33. Ten RM, McKinstry MJ, Trushin SA, Asin S, Paya CV: The Signal Transduction Pathway of CD23 (FceRIIb) Targets IKB Kinase. J Immunol 1999, 163: 3851-3857

34. Karin M, Lin A: NF-κB at the crossroads of life and death. Nature Immunol 2002, 3: 221-227.

35. Lappas M, Yee K, Permezel M, Rice GE: Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-xB and IκB kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology 2005, 146: 1491-1497.

36. Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M: Inhibition of p38 MAP kinase and RICK/NF-xB-signaling suppresses inflammatory bowel disease. FASEB J 2004, 18: 1550-1552.

37. Schmitz H, Fromm M, Bentzel CJ, Scholz P, Detjen K, Mankertz J, Bode H, Eppe J-H, Riecken E-O, Schulzke J-D: Tumor necrosis factor-alpha (TNF-α) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci 1999, 112: 137-146.

38. Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, Wallace JL, Hollenberg MD, Bunnett NW, Garcia-Villar R, Bueno L, Vergnolle N: Induction of intestinal inflammation in mouse by activation of protease-activated receptor-2. Am J Pathol 2002, 161: 1903-1915.

39. Welker P, Grabbe J, Zuberbier T, Grutzkau A, Henz BM: GM-CSF downmodulates c-kit, Fc(epsilon)RI(alpha) and GM-CSF receptor expression as well as histamine and tryptase levels in cultured human mast cells. Arch Dermatol Res 2001, 293: 249-258.

40. Makishima M, Kanatani Y, Yamamoto-Yamaguchi Y, Honma Y: Enhancement of activity of lalpha, 25-dihydroxyvitamin D3 for growth inhibition and differentiation induction of human myelomonocytic leukemia cells by tretinoin tocoferil, an alpha-tocopherol ester of all-trans retinoic acid. Blood 1996, 87: 3384-3394.

41. Tu Y, Perdue MH: CD23-mediated transport of IgE/immune complexes across human intestinal epithelium: role of p38 MAPK. Am J Physiol Gastrointest Liver Physiol 2006, 291: G532-G538.
42. Yu LC, Yang PC, Berin MC, Di Leo V, Conrad DH, McKay DM, Satoskar AR, Perdue MH: Enhanced transepithelial antigen transport in intestine of allergic mice is mediated by IgE/CD23 and regulated by interleukin-4. Gastroenterology 2001, 121: 370-381.

43. Beasley R, Roche WR, Roberts JA, Holgate ST: Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989, 139: 806-817.

44. Alexandrakis MG, Kyriakou DS, Seretakis D, Boucher W, Letourneau R, Kempuraj D, Theocharides TC: Inhibitory effect of retinoic acid on proliferation, maturation and tryptase level in human leukemic mast cells (HMC-1). Int J Immunopathol Pharmacol 2003, 16: 43-47.

45. Woods M, Wood EG, Mitchell JA, Warner TD: Signal transduction pathways involved in cytokine stimulation of endothelin-1 release from human vascular smooth muscle cells. J Cardiovasc Pharmacol 2000, 36(5 Suppl 1): S407-S409.

46. Jian Y-T, Mai G-F, Wang J-D, Zhang Y-L, Luo R-C, Fang Y-X: Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 2005, 11: 1747-1752.

47. Hagar HH, El-Medany A, El-Eter E, Arafa M: Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats. Eur J Pharmacol 2007, 554: 69-77.